Lung cancer treatment depends on two main factors: the type of lung cancer you have and how far it has spread. The two major types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), follow different treatment paths. Options range from surgery and radiation to chemotherapy, targeted therapy, and immunotherapy, often used in combination. Early-stage cancers caught before they spread have dramatically better outcomes, with a five-year survival rate of 67% for localized NSCLC compared to 12% once it has spread to distant parts of the body.
Why the Type and Stage Matter
About 80% to 85% of lung cancers are non-small cell, which tends to grow more slowly and is more likely to be caught at a stage where surgery can remove it. Small cell lung cancer is less common but more aggressive, often already widespread by the time it’s diagnosed. Its five-year survival rates are considerably lower: 34% for localized disease and just 4% when distant.
Staging determines how far the cancer has traveled. Localized means it’s still confined to the lung. Regional means it has reached nearby lymph nodes. Distant, or stage IV, means it has spread to other organs like the brain, bones, or liver. Your treatment plan is built around this staging, and it may involve a single approach or a layered combination.
Surgery for Early-Stage Cancer
When lung cancer is found early (stages I, II, and sometimes III), surgery is typically the first-line treatment. The goal is to remove all cancerous tissue along with a margin of healthy tissue around it. There are three main types of lung surgery:
- Wedge resection: removes a small, wedge-shaped section of lung tissue. This is used for very small tumors or when preserving as much lung as possible is important.
- Lobectomy: removes one entire lobe of the lung (the right lung has three lobes, the left has two). This is the most common surgery for early-stage lung cancer.
- Pneumonectomy: removes an entire lung. This is reserved for larger tumors or those in a position that makes a smaller resection impossible.
Recovery time depends on the surgical approach. Minimally invasive techniques using small incisions and a camera often allow people to return to regular activities within about two weeks. Traditional open surgery, which requires a larger incision between the ribs, typically means limiting activity for about a month. Full recovery from any lung resection can take weeks to months.
After surgery, many patients receive additional treatment to kill any remaining cancer cells. This might include chemotherapy before surgery (called neoadjuvant therapy) to shrink the tumor, or chemotherapy and immunotherapy afterward (adjuvant therapy) to reduce the chance of recurrence. For patients whose tumors carry specific genetic changes, targeted therapy drugs may also be used after surgery.
Radiation Therapy
Radiation uses high-energy beams to destroy cancer cells. It plays different roles depending on the situation: as a primary treatment for people who can’t have surgery, as a complement to surgery to catch remaining cells, or as a way to shrink tumors and relieve symptoms in advanced disease.
There are two broad approaches. Conventional external beam radiation delivers smaller doses over many sessions, sometimes spanning several weeks. This gradual approach is safer when tumors sit near sensitive structures like the heart or spinal cord. Stereotactic body radiation therapy (SBRT) takes the opposite approach, delivering very high, precisely targeted doses in just one to five sessions. SBRT is particularly useful for small, early-stage tumors in patients who aren’t candidates for surgery, and for cancers that have spread to only a limited number of spots in the body. It’s also an option when a tumor is in an area that was previously treated with radiation.
For limited-stage small cell lung cancer, radiation is often given at the same time as chemotherapy, a combination called chemoradiation.
Chemotherapy
Chemotherapy uses drugs that circulate through the bloodstream to kill rapidly dividing cells. It remains a cornerstone of lung cancer treatment, especially for cancers that have spread beyond the lung or aren’t removable with surgery.
First-line chemotherapy for lung cancer usually involves a platinum-based drug paired with a second agent. Common combinations include carboplatin with paclitaxel and gemcitabine with cisplatin. These are typically given in cycles, with rest periods between them to let the body recover. For advanced NSCLC, chemotherapy is now frequently combined with immunotherapy drugs, which has improved outcomes compared to chemotherapy alone.
Small cell lung cancer is initially very responsive to chemotherapy, which is why it’s the primary treatment for this type. The challenge is that SCLC tends to come back, often with resistance to the same drugs.
Targeted Therapy and Biomarker Testing
One of the biggest advances in lung cancer treatment has been the discovery that certain genetic mutations drive tumor growth, and that drugs can be designed to block those specific mutations. Before starting treatment for advanced NSCLC, doctors test tumor tissue for these genetic changes through biomarker testing.
The most well-known mutations and their treatments include:
- EGFR mutations: common in non-smokers and people of East Asian descent. Drugs like osimertinib block the faulty protein these mutations produce.
- ALK rearrangements: more common in younger patients who have never smoked. Drugs such as alectinib and lorlatinib target this abnormality.
- KRAS G12C mutations: once considered impossible to treat, now targetable with drugs like sotorasib.
- ROS1 rearrangements, RET fusions, MET mutations, and NTRK fusions: each has its own class of targeted drugs.
Targeted therapies are taken as daily pills in most cases, and they tend to cause fewer of the side effects associated with traditional chemotherapy. They work best in tumors that carry the specific mutation they’re designed for, which is why biomarker testing is so important. Without it, patients may miss out on treatments that could be highly effective for their particular cancer.
Immunotherapy
Immunotherapy helps your immune system recognize and attack cancer cells that it would otherwise overlook. Cancer cells often carry a protein called PD-L1 on their surface that acts like a disguise, telling immune cells to stand down. Immunotherapy drugs called checkpoint inhibitors block this signal, essentially removing the disguise so your T cells can find and kill the cancer.
The main checkpoint inhibitors used in lung cancer target either PD-1 (on immune cells) or PD-L1 (on cancer cells). Pembrolizumab and nivolumab are among the most commonly used. For advanced NSCLC without a targetable genetic mutation, immunotherapy combined with chemotherapy has become a standard first-line treatment. In limited-stage small cell lung cancer, durvalumab may be given after chemoradiation if the cancer hasn’t grown.
Immunotherapy can cause a distinct set of side effects because it activates the immune system broadly, not just against cancer. The most common immune-related reactions affect the skin, gut, liver, lungs, and hormone-producing glands. Mild reactions are managed while continuing treatment, but more severe reactions may require pausing the drug and using medications to calm the immune response. In rare cases of serious reactions, immunotherapy is stopped permanently.
Palliative Care and Quality of Life
Palliative care focuses on relieving pain, stress, and other symptoms of the disease rather than treating the cancer itself. It’s not the same as hospice or end-of-life care. It can and should be started alongside active cancer treatment.
A large VA study of over 23,000 patients with advanced lung cancer found that those who received palliative care between one month and one year after diagnosis lived longer than those who never received it. Palliative care started more than a year after diagnosis showed no survival benefit. The American Society of Clinical Oncology recommends starting palliative care within eight weeks of an advanced lung cancer diagnosis.
The survival benefit likely comes from several factors. Palliative care helps patients manage symptoms that can worsen overall health, improves mood and quality of life, and supports better decision-making about treatment intensity. Patients who receive palliative care are also less likely to die in an intensive care unit, suggesting it helps avoid aggressive interventions that may cause more harm than benefit in later stages of the disease.
Screening Catches Cancer Earlier
Because treatment is far more effective when lung cancer is found early, screening matters. Current guidelines recommend annual low-dose CT scans for people aged 50 and older with a smoking history of 20 years or more. Unlike some other screening recommendations, there is no upper age cutoff and no requirement based on how long ago you quit smoking. The rationale is straightforward: the risk of lung cancer persists for former smokers regardless of when they stopped.